litlas
Log inCreate account

Sandra P. D’Angelo

Active 2005–2025

Also published as
Sandra P. D'Angelo
97
Papers
21,266
Citations
50
h-index
89
i10-index

Citations

Citations per year for Sandra P. D’Angelo1976: 1 citations1977: 1 citations1996: 2 citations1997: 4 citations2006: 3 citations2007: 3 citations2008: 3 citations2009: 6 citations2010: 6 citations2011: 7 citations2012: 12 citations2013: 34 citations2014: 45 citations2015: 95 citations2016: 231 citations2017: 332 citations2018: 299 citations2019: 1,095 citations2020: 1,427 citations2021: 1,370 citations2022: 1,071 citations2023: 792 citations2024: 1,128 citations2025: 516 citations2026: 11 citations1978–1995: no citations, so these years are not shown1998–2005: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,905 citing papers, 27% of this breakdownChina: 1,696 citing papers, 15.8% of this breakdownItaly: 630 citing papers, 5.9% of this breakdownGermany: 545 citing papers, 5.1% of this breakdownUnited Kingdom: 533 citing papers, 5% of this breakdownFrance: 482 citing papers, 4.5% of this breakdownJapan: 343 citing papers, 3.2% of this breakdownCanada: 323 citing papers, 3% of this breakdownAustralia: 317 citing papers, 2.9% of this breakdownNetherlands: 302 citing papers, 2.8% of this breakdownSpain: 283 citing papers, 2.6% of this breakdownSwitzerland: 268 citing papers, 2.5% of this breakdown
0%27%Other 19.7%

Institutions

Fields

  • Medicine77.8%
  • Biochemistry, Genetics and Molecular Biology12.6%
  • Immunology and Microbiology7.3%
  • Engineering0.7%
  • Computer Science0.3%
  • Neuroscience0.3%
  • Other1%

Topics

  • Cancer Immunotherapy and Biomarkers17%
  • CAR-T cell therapy research6.3%
  • Immunotherapy and Immune Responses6%
  • Sarcoma Diagnosis and Treatment3.4%
  • Lung Cancer Treatments and Mutations3.3%
  • Cancer Genomics and Diagnostics3.2%
  • Other60.8%

Coauthors

All papers

Open in search
  1. Tumor mutational load predicts survival after immunotherapy across multiple cancer types

    Authors: Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari, Matthew D. Hellmann, Ronglai Shen, Yelena Y. Janjigian, David Barron, Ahmet Zehir, Emmet Jordan, Antonio Omuro, Thomas Kaley, Sviatoslav M. Kendall, Robert J. Motzer, A. Ari Hakimi, Martin H. Voss, Paul Russo, Jonathan E. Rosenberg, Gopa Iyer, Bernard H. Bochner, Dean F. Bajorin, Hikmat Al‐Ahmadie, Jamie E. Chaft, Charles M. Rudin, Gregory J. Riely, Shrujal S. Baxi, Alan L. Ho, Richard J. Wong, David G. Pfister, Jedd D. Wolchok, Christopher A. Barker, Philip H. Gutin, Cameron Brennan, Viviane Tabar, Ingo K. Mellinghoff, Lisa M. DeAngelis, Charlotte E. Ariyan, Nancy Y. Lee, William D. Tap, Mrinal M. Gounder, Sandra P. D’Angelo, Leonard B. Saltz, Zsofia K. Stadler, Howard I. Scher, José Baselga, Pedram Razavi, Christopher A. Klebanoff, Rona Yaeger, Neil H. Segal, Geoffrey Y. Ku, Ronald P. DeMatteo, Marc Ladanyi, Naiyer A. Rizvi, Michael F. Berger, Nadeem Riaz, David B. Solit, Timothy A. Chan, Luc G.T. Morris - Nature Genetics 2019 cited by 4,358

  2. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

    Authors: Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack, Brian A. Van Tine, Scott M. Schuetze, James Hu, Sandra P. D’Angelo, Steven Attia, Richard F. Riedel, Dennis A. Priebat, Sujana Movva, Lara E. Davis, Scott H. Okuno, Damon R. Reed, John Crowley, Lisa H. Butterfield, Ruth Salazar, Jaime Rodriguez‐Canales, Alexander J. Lazar, Ignacio I. Wistuba, Laurence H. Baker, Robert G. Maki, Denise K. Reinke, Shreyaskumar Patel - The Lancet Oncology 2017 cited by 1,423

  3. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

    Authors: Jeffrey S. Weber, Sandra P. D’Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer, Bart Neyns, Christoph Höeller, Nikhil I. Khushalani, Wilson H. Miller, Christopher D. Lao, Gerald P. Linette, L. Thomas, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Michele Maio, Mario Sznol, Paolo A. Ascierto, Peter Mohr, Bartosz Chmielowski, Alan H. Bryce, Inge Marie Svane, Jean‐Jacques Grob, Angela M. Krackhardt, Christine E. Horak, Alexandre Lambert, Arvin Yang, James Larkin - The Lancet Oncology 2015 cited by 2,666

  4. Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial

    Authors: Sandra P. D’Angelo, Dejka M. Araujo, Albiruni R. Abdul Razak, Mark Agulnik, Steven Attia, Jean‐Yves Blay, Irene Carrasco García, John A. Charlson, Edwin Choy, George D. Demetri, Mihaela Druta, Édouard Forcade, Kristen N. Ganjoo, John Glod, Vicki L. Keedy, Axel Le Cesne, David A. Liebner, Víctor Moreno, Seth M. Pollack, Scott M. Schuetze, Gary K. Schwartz, Sandra J. Strauss, William D. Tap, Fiona Thistlethwaite, Claudia Maria Valverde Morales, Michael J. Wagner, Breelyn A. Wilky, Cheryl McAlpine, Laura Hudson, Jean‐Marc Navenot, Tianjiao Wang, Jane P. F. Bai, Stavros Rafail, Ruoxi Wang, Amy Sun, Lilliam Fernandes, Erin Van Winkle, Erica Elefant, Colin Lunt, Elliot Norry, Dennis Williams, Swethajit Biswas, Brian Andrew Van Tine - The Lancet 2024 cited by 263

  5. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials

    Authors: Sandra P. D’Angelo, Michelle R. Mahoney, Brian Andrew Van Tine, James N. Atkins, Mohammed Milhem, Balkrishna Jahagirdar, Cristina R. Antonescu, Elise Horvath, William D. Tap, Gary K. Schwartz, Howard Streicher - The Lancet Oncology 2018 cited by 748

  6. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

    Authors: Troy Z. Horvat, Nelly G. Adel, Thu-Oanh Dang, Parisa Momtaz, Michael A. Postow, Margaret K. Callahan, Richard D. Carvajal, Mark A. Dickson, Sandra P. D’Angelo, Kaitlin M. Woo, Katherine S. Panageas, Jedd D. Wolchok, Paul B. Chapman - Journal of Clinical Oncology 2015 cited by 1,073

  7. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets

    Authors: Benjamin A. Nacev, Francisco Sánchez-Vega, Shaleigh Smith, Cristina R. Antonescu, Evan Rosenbaum, Hongyu Shi, Cerise Tang, Nicholas D. Socci, Satshil Rana, Rodrigo Gularte‐Mérida, Ahmet Zehir, Mrinal M. Gounder, Timothy G. Bowler, Anisha Luthra, Bhumika Jadeja, Azusa Okada, Jonathan A. Strong, Jake Stoller, Jason E. Chan, Ping Chi, Sandra P. D’Angelo, Mark A. Dickson, Ciara M. Kelly, Mary Louise Keohan, Sujana Movva, Katherine A. Thornton, Paul A. Meyers, Leonard H. Wexler, Emily K. Slotkin, Julia Glade Bender, Neerav Shukla, Martee L. Hensley, John H. Healey, Michael P. LaQuaglia, Kaled M. Alektiar, Aimeé M. Crago, Sam S. Yoon, Brian R. Untch, Sarah Chiang, Narasimhan P. Agaram, Meera Hameed, Michael F. Berger, David B. Solit, Nikolaus Schultz, Marc Ladanyi, Samuel Singer, William D. Tap - Nature Communications 2022 cited by 211

  8. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

    Authors: Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Célèste Lebbé, Gerald P. Linette, Michèle Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Kevin M. Chin, Lisa Mahnke, Anja von Heydebreck, Jean-Marie Cuillerot, Paul Nghiem - The Lancet Oncology 2016 cited by 1,215

  9. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

    Authors: C. Gomez-Roca, Antoîne Italiano, Christophe Le Tourneau, Philippe A. Cassier, Maud Toulmonde, Sandra P. D’Angelo, Mario Campone, Kristy Weber, Delphine Loirat, Michael A. Cannarile, Anna Maria Jegg, Carola H. Ries, R D Christen, Georgina Meneses‐Lorente, Wolfgang Jacob, Irina Klaman, Chia-Huey Ooi, Carl Watson, Kathrin Wonde, Bernhard Reis, Francesca Michielin, Dominik Rüttinger, Jean‐Pierre Delord, Jean‐Yves Blay - Annals of Oncology 2019 cited by 202

  10. Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS -Mutant Cancers

    Authors: Snjezana Doğan, Ronglai Shen, Daphne Ang, Melissa L. Johnson, Sandra P. D’Angelo, Paul K. Paik, Edyta B. Brzostowski, Gregory J. Riely, Mark G. Kris, Maureen F. Zakowski, Marc Ladanyi - Clinical Cancer Research 2012 cited by 619

  11. Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis

    Authors: Sandra P. D’Angelo, James Larkin, Jeffrey A. Sosman, Célèste Lebbé, Benjamin Brady, Bart Neyns, Henrik Schmidt, Jessica C. Hassel, F. Stephen Hodi, Paul Lorigan, Kerry J. Savage, Wilson H. Miller, Peter Mohr, Iván Márquez‐Rodas, J. Charles, Martin Kaatz, Mario Sznol, Jeffrey S. Weber, Alexander N. Shoushtari, Mary Ruisi, Joel Jiang, Jedd D. Wolchok - Journal of Clinical Oncology 2017 cited by 643

  12. Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma

    Authors: Sandra P. D’Angelo, Luca Melchiori, Melinda S. Merchant, Donna Bernstein, John Glod, Rosandra N. Kaplan, Stephan A. Grupp, William D. Tap, Karen Chagin, Gwendolyn K. Binder, Samik Basu, Daniel E. Lowther, Ruoxi Wang, Natalie Bath, Alex J. Tipping, Gareth Betts, Indu Ramachandran, Jean‐Marc Navenot, Hua Zhang, Daniel K. Wells, Erin Van Winkle, Gabor Kari, Trupti Trivedi, Tom Holdich, Lini Pandite, Rafael G. Amado, Crystal L. Mackall - Cancer Discovery 2018 cited by 435

  13. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

    Authors: James Larkin, David R. Minor, Sandra P. D’Angelo, Bart Neyns, Michael Smylie, Wilson H. Miller, Ralf Gutzmer, Gerald P. Linette, Bartosz Chmielowski, Christopher D. Lao, Paul Lorigan, Kenneth F. Grossmann, Jessica C. Hassel, Mario Sznol, Adil Daud, Jeffrey A. Sosman, Nikhil I. Khushalani, Dirk Schadendorf, Christoph Höeller, Dana Walker, George Kong, Christine E. Horak, Jeffrey S. Weber - Journal of Clinical Oncology 2017 cited by 510

  14. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors

    Authors: Tae Won Kim, Philippe L. Bédard, Patricia LoRusso, Michael S. Gordon, Johanna C. Bendell, Do‐Youn Oh, Myung‐Ju Ahn, Elena Garralda, Sandra P. D’Angelo, Jayesh Desai, F. Stephen Hodi, Zev A. Wainberg, Jean‐Pierre Delord, Phillippe A. Cassier, Andrés Cervantes, Marta Gil-Martín, Benjamin Wu, Namrata S. Patil, Yanling Jin, Tien Hoang, Diana Mendus, Xiaohui Wen, Raymond D. Meng, Byoung Chul Cho - JAMA Oncology 2023 cited by 63

  15. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab

    Authors: Ciara M. Kelly, Cristina R. Antonescu, Timothy G. Bowler, Rodrigo Ramella Munhoz, Ping Chi, Mark A. Dickson, Mrinal M. Gounder, Mary Louise Keohan, Sujana Movva, Reena Dholakia, Hamza Ahmad, Matthew D. Biniakewitz, Mercedes M. Condy, Haley T. Phelan, Margaret K. Callahan, Phillip Wong, S. J. Singer, Charlotte E. Ariyan, Edmund K. Bartlett, Aimeé M. Crago, Sam S. Yoon, Sinchun Hwang, Joseph P. Erinjeri, Li‐Xuan Qin, William D. Tap, Sandra P. D’Angelo - JAMA Oncology 2020 cited by 205

  16. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study

    Authors: Sandra P. D’Angelo, Célèste Lebbé, Laurent Mortier, Andrew S. Brohl, Nicola Fazio, Jean‐Jacques Grob, Natalie Prinzi, Glenn J. Hanna, Jessica C. Hassel, Felix Kiecker, Sara Georges, Barbara Ellers‐Lenz, Parantu K. Shah, Gülseren Güzel, Paul Nghiem - Journal for ImmunoTherapy of Cancer 2021 cited by 140

  17. A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma

    Authors: Ciara M. Kelly, Li‐Xuan Qin, Karissa Whiting, Allison L. Richards, Viswatej Avutu, Jason E. Chan, Ping Chi, Mark A. Dickson, Mrinal M. Gounder, Mary Louise Keohan, Sujana Movva, Benjamin A. Nacev, Evan Rosenbaum, Travis E. Adamson, Samuel Singer, Edmund K. Bartlett, Aimeé M. Crago, Sam S. Yoon, Sinchun Hwang, Joseph P. Erinjeri, Cristina R. Antonescu, William D. Tap, Sandra P. D’Angelo - Clinical Cancer Research 2023 cited by 69

  18. Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib

    Authors: Mark A. Dickson, Gary K. Schwartz, Mary Louise Keohan, Sandra P. D’Angelo, Mrinal M. Gounder, Ping Chi, Cristina R. Antonescu, Jonathan Landa, Li‐Xuan Qin, Aimeé M. Crago, Samuel Singer, Andrew Koff, William D. Tap - JAMA Oncology 2016 cited by 324

  19. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial

    Authors: Howard L. Kaufman, Jeffery S. Russell, Omid Hamid, Shailender Bhatia, Patrick Terheyden, Sandra P. D’Angelo, Kent C. Shih, Célèste Lebbé, Michèle Milella, Isaac Brownell, Karl D. Lewis, Jochen H. Lorch, Anja von Heydebreck, Meliessa Hennessy, Paul Nghiem - Journal for ImmunoTherapy of Cancer 2018 cited by 330

  20. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma

    Authors: Indu Ramachandran, Daniel E. Lowther, Rebecca Dryer-Minnerly, Ruoxi Wang, Svetlana Fayngerts, Daniel Álvarez Núñez, Gareth Betts, Natalie Bath, Alex J. Tipping, Luca Melchiori, Jean-Marc Navenot, John Glod, Crystal L. Mackall, Sandra P. D’Angelo, Dejka M. Araujo, Warren Chow, George D. Demetri, Mihaela Druta, Brian Andrew Van Tine, Stephan A. Grupp, Albiruni R. Abdul Razak, Breelyn A. Wilky, Malini Iyengar, Trupti Trivedi, Erin Van Winkle, Karen Chagin, Rafael G. Amado, Gwendolyn K. Binder, Samik Basu - Journal for ImmunoTherapy of Cancer 2019 cited by 145

  21. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma

    Authors: Sandra P. D’Angelo, Allison L. Richards, Anthony P. Conley, Hyung Jun Woo, Mark A. Dickson, Mrinal M. Gounder, Ciara M. Kelly, Mary Louise Keohan, Sujana Movva, Katherine A. Thornton, Evan Rosenbaum, Ping Chi, Benjamin A. Nacev, Jason E. Chan, Emily K. Slotkin, Hannah Kiesler, Travis E. Adamson, Lilan Ling, Pavitra Rao, Shreyaskumar Patel, Jonathan A. Livingston, Samuel Singer, Narasimhan P. Agaram, Cristina R. Antonescu, Andrew Koff, Joseph P. Erinjeri, Sinchun Hwang, Li‐Xuan Qin, Mark T.A. Donoghue, William D. Tap - Nature Communications 2022 cited by 60

  22. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial

    Authors: Sandra P. D’Angelo, Shailender Bhatia, Andrew S. Brohl, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Célèste Lebbé, Karl D. Lewis, Gerald P. Linette, Michèle Milella, Sara Georges, Parantu K. Shah, Barbara Ellers‐Lenz, Marcis Bajars, Gülseren Güzel, Paul Nghiem - Journal for ImmunoTherapy of Cancer 2020 cited by 197

  23. Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour

    Authors: Philippe A. Cassier, Antoîne Italiano, Carlos Gomez‐Roca, Christophe Le Tourneau, Maud Toulmonde, Sandra P. D’Angelo, Kristy Weber, Delphine Loirat, Wolfgang Jacob, Anna-Maria Jegg, Francesca Michielin, R D Christen, Carl Watson, Michael A. Cannarile, Irina Klaman, K. Abiraj, Carola H. Ries, Maja Weisser, Dominik Rüttinger, Jean‐Yves Blay, Jean‐Pierre Delord - European Journal of Cancer 2020 cited by 68

  24. Recurrent CIC Gene Abnormalities in Angiosarcomas

    Authors: Shih‐Chiang Huang, Lei Zhang, Yun-Shao Sung, Chun‐Liang Chen, Yu‐Chien Kao, Narasimhan P. Agaram, Samuel Singer, William D. Tap, Sandra P. D’Angelo, Cristina R. Antonescu - The American Journal of Surgical Pathology 2016 cited by 206